Published on : Nov 22, 2016
ALBANY, NY, Nov 22, 2016: Besides presenting a detailed assessment of the various factors influencing the market’s trajectory, the report provides an analysis of the competition prevailing in the market. The market participants are thus profiled and their strategies are discussed at length to gauge the prevailing demand and supply forces. The report is intended to help participants develop winning business strategies after evaluating the trends prevalent in the global acute coronary syndrome (ACS) market.
In also includes exhaustive data to help existing players identify the potential competitors and strong product-portfolios. Information compiled in the report is aimed at facilitating the development of business strategies by presenting insights into the prevailing trends and the market’s competitive landscape.
The global acute coronary syndrome market is driven by the physician confidence and increasing use of PCSK9 inhibitor class. The segment is projected to comprise four major players by the end of the forecast period. According to the report, ETC-1002, which is a new lipid lowering therapy, is expected to emerge as a major contributor to the market, vying to establish dominance by the end of the forecast period. By the time, the segment is also projected to gain a majority of patients in the statin intolerant ACS population.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=862829
Despite witnessing strong growth, the generic erosion of the primary antiplatelet therapies will create major hindrances for the market. The drugs likely to lose patent by the end of the report’s forecast period are Effient and Brilinta. Both of them accounted for a significant share of revenue generated from sales in the market. Considering the looming patent expiry of the blockbuster drugs, the pace of gains witnessed by the market is forecast to decelerate over the forecast period.
Analysts therefore predict the dynamics of the global ACS market to rapidly shift towards addressing atherosclerotic burden commonly associated with acute coronary syndrome. Despite the impending patent expirations, the report has identified the prevalence of high level of unmet medical needs across developing economies as key opportunity for the market. This can be achieved by developing optimal agents for secondary prevention aimed at controlling lipid levels. The method can also help repair the damaged myocardium, which is mostly an outcome of the post myocardial infarction, thus preventing comorbidities such as cardiac arrest.
To study the opportunities for the market, the report includes a detailed pipeline analysis. To analyze the prevailing vendor landscape, it also profiles companies such as Amgen, AstraZeneca, Cerenis Therapeutics, Daiichi Sankyo, Esperion Therapeutics, Eli Lilly, GlaxoSmithKline, Merck & Co., Sanofi, Pfizer, and others.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com